National Institute of Diabetes and Digestive and Kidney Diseases: Notice of Meetings, 46308-46309 [2015-19024]
Download as PDF
<![CDATA[
46308
Federal Register / Vol. 80, No. 149 / Tuesday, August 4, 2015 / Notices
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: July 29, 2015.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–19030 Filed 8–3–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases: Notice
of Closed Meetings
tkelley on DSK3SPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Endocrinology
Ancillary Studies.
Date: August 13, 2015.
Time: 4:30 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Maria E. Davila-Bloom,
Ph.D., Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 758, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7637, davila-bloomm@
extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Sensitive Obesity.
Date: August 31, 2015.
Time: 1:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Michele L. Barnard, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 753, 6707 Democracy Boulevard,
VerDate Sep<11>2014
18:45 Aug 03, 2015
Jkt 235001
Bethesda, MD 20892–2542, (301) 594–8898,
barnardm@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Biomarkers for TID
and Kidney Disease (PAR–13–228:
Biomarkers for Diabetes, Digestive and
Kidney and Urologic Diseases using
Repository Biosamples (R01).
Date: October 1, 2015.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Najma Begum, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 749, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8894,
begumn@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK: Digestive
Diseases Program Projects (P01).
Date: October 14, 2015.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Najma Begum, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 749, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8894,
begumn@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; PAR–12–265:
NIDDK Ancillary Studies on CKD and
Diabetic Nephropathy (R01).
Date: October 15, 2015.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Najma Begum, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 749, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8894,
begumn@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: July 28, 2015.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–19026 Filed 8–3–15; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases: Notice
of Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of meetings of the National
Diabetes and Digestive and Kidney
Diseases Advisory Council.
The meetings will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Diabetes and
Digestive and Kidney Diseases Advisory
Council.
Date: September 9, 2015.
Open: 8:30 a.m. to 12:00 p.m.
Agenda: To present the Director’s Report
and other scientific presentations.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 10, Bethesda, MD 20892.
Closed: 3:45 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 10, Bethesda, MD 20892.
Contact Person: Brent B. Stanfield, Ph.D.,
Director, Division of Extramural Activities,
National Institutes of Diabetes And Digestive
and Kidney Diseases, 6707 Democracy Blvd.
Room 715, Msc 5452, Bethesda, MD 20892,
(301) 594–8843, stanfibr@niddk.nih.gov.
Name of Committee: National Diabetes and
Digestive and Kidney Diseases Advisory
Council; Diabetes, Endocrinology and
Metabolic Diseases Subcommittee.
Date: September 9, 2015.
Closed: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 10, Bethesda, MD 20892.
Open: 2:00 p.m. to 3:30 p.m.
Agenda: To review the Division’s scientific
and planning activities.
E:\FR\FM\04AUN1.SGM
04AUN1
tkelley on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 149 / Tuesday, August 4, 2015 / Notices
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 10, Bethesda, MD 20892.
Contact Person: Brent B. Stanfield, Ph.D.,
Director, Division of Extramural Activities,
National Institutes of Diabetes And Digestive
and Kidney Diseases, 6707 Democracy Blvd.
Room 715, MSC 5452, Bethesda, MD 20892,
(301) 594–8843, stanfibr@niddk.nih.gov.
Name of Committee: National Diabetes and
Digestive and Kidney Diseases Advisory
Council; Kidney, Urologic and Hematologic
Diseases Subcommittee.
Date: September 9, 2015.
Open: 1:00 p.m. to 3:00 p.m.
Agenda: To review the Division’s scientific
and planning activities.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 7, Bethesda, MD 20892.
Closed: 3:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 7, Bethesda, MD 20892.
Contact Person: Brent B. Stanfield, Ph.D.,
Director, Division of Extramural Activities,
National Institutes of Diabetes And Digestive
and Kidney Diseases, 6707 Democracy Blvd.
Room 715, MSC 5452, Bethesda, MD 20892,
(301) 594–8843, stanfibr@niddk.nih.gov.
Name of Committee: National Diabetes and
Digestive and Kidney Diseases Advisory
Council; Digestive Diseases and Nutrition
Subcommittee.
Date: September 9, 2015.
Open: 1:00 p.m. to 3:00 p.m.
Agenda: To review the Division’s scientific
and planning activities.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 6, Bethesda, MD 20892.
Closed: 3:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 6, Bethesda, MD 20892.
Contact Person: Brent B. Stanfield, Ph.D.,
Director, Division Of Extramural Activities,
National Institutes of Diabetes And Digestive
and Kidney Diseases, 6707 Democracy Blvd.
Room 715, MSC 5452, Bethesda, MD 20892
(301) 594–8843, stanfibr@niddk.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page:
www.niddk.nih.gov/fund/divisions/DEA/
Council/coundesc.htm., where an agenda and
VerDate Sep<11>2014
18:45 Aug 03, 2015
Jkt 235001
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: July 29, 2015.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–19024 Filed 8–3–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology descriptions follow.
Interferon Alpha Hybrids
Description of Technology: Available
for licensing are hybrid interferon alpha
(INF-alpha) polypeptides constructed by
combinations of INFalpha21b and
INFalpha2c, and mutants of these
hybrids. These hybrid constructs have
resulted in novel IFNs that either
combine different biological properties
from the parent proteins or have
significantly different biological activity
from both the parents in antiproliferative, anti-viral, or competitive
Frm 00076
Fmt 4703
binding properties. For instance, the
hybrid designated HY–3 has higher antiproliferative activity in Daudi, WISH,
and primary human lymphocyte cells
exhibiting approximately 6 times higher
anti-proliferative activity than either
parent IFN. These IFN hybrids provide
a powerful tool for studying the
structure-function relationship of these
molecules. The engineered IFN-alpha
proteins may have important new
therapeutic applications and may
provide greater insights into
understanding of the clinical activities
of existing IFN-alphas.
Also available for licensing are hybrid
INF-alpha nucleic acids encoding the
hybrid polypeptides as well as cells,
vectors, pharmaceutical compositions
with these nucleic acid sequences.
Potential Commercial Applications
• Anti-viral and cancer therapeutics
• Research tool to study IFN-alpha
functions
Competitive Advantages
Notice.
SUMMARY:
PO 00000
46309
Sfmt 4703
• Ease of manufacture
• Strong anti-viral activity
Development Stage: In vitro data
available.
Inventors: Kathryn C. Zoon (NIAID),
Joseph B. Bekisz (NIAID), Mark P. Hayes
(FDA), Renqiu Hu (FDA).
Publications
1. Hu R, et al. Protein engineering of
interferon alphas. Methods Mol Med.
2005;116:69–80. [PMID 16000855]
2. Hu R, et al. Human IFN-alpha protein
engineering: the amino acid residues at
positions 86 and 90 are important for
antiproliferative activity. J Immunol.
2001 Aug 1;167(3):1482–9. [PMID
11466368]
3. Hu R, et al. Divergence of binding,
signaling, and biological responses to
recombinant human hybrid IFN. J
Immunol. 1999 Jul 15;163(2):854–60.
[PMID 10395679]
Intellectual Property: HHS Reference
No. E–068–1998/0—
• US Patent No. 6,685,933 issued 03
Feb 2004
• US Patent No. 7,235,232 issued 26 Jun
2007
Licensing Contact: Peter Soukas; 301–
435–4646; ps193c@nih.gov.
Novel Treatment for Anemia and
Polycythemia: AVPR1B Molecules
Modulating Erythropoiesis
Description of Technology: Anemia
can be caused by chronic diseases,
chemotherapy, or radiation.
Erythropoietin is commonly used to
stimulate red blood cell production for
anemia treatment, but it takes about a
week to manifest its clinical effect. The
E:\FR\FM\04AUN1.SGM
04AUN1
]]>Agencies
[Federal Register Volume 80, Number 149 (Tuesday, August 4, 2015)]
[Notices]
[Pages 46308-46309]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-19024]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases:
Notice of Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of meetings of the
National Diabetes and Digestive and Kidney Diseases Advisory Council.
The meetings will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Diabetes and Digestive and Kidney
Diseases Advisory Council.
Date: September 9, 2015.
Open: 8:30 a.m. to 12:00 p.m.
Agenda: To present the Director's Report and other scientific
presentations.
Place: National Institutes of Health, Building 31, 31 Center
Drive, Conference Room 10, Bethesda, MD 20892.
Closed: 3:45 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Building 31, 31 Center
Drive, Conference Room 10, Bethesda, MD 20892.
Contact Person: Brent B. Stanfield, Ph.D., Director, Division of
Extramural Activities, National Institutes of Diabetes And Digestive
and Kidney Diseases, 6707 Democracy Blvd. Room 715, Msc 5452,
Bethesda, MD 20892, (301) 594-8843, stanfibr@niddk.nih.gov.
Name of Committee: National Diabetes and Digestive and Kidney
Diseases Advisory Council; Diabetes, Endocrinology and Metabolic
Diseases Subcommittee.
Date: September 9, 2015.
Closed: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Building 31, 31 Center
Drive, Conference Room 10, Bethesda, MD 20892.
Open: 2:00 p.m. to 3:30 p.m.
Agenda: To review the Division's scientific and planning
activities.
[[Page 46309]]
Place: National Institutes of Health, Building 31, 31 Center
Drive, Conference Room 10, Bethesda, MD 20892.
Contact Person: Brent B. Stanfield, Ph.D., Director, Division of
Extramural Activities, National Institutes of Diabetes And Digestive
and Kidney Diseases, 6707 Democracy Blvd. Room 715, MSC 5452,
Bethesda, MD 20892, (301) 594-8843, stanfibr@niddk.nih.gov.
Name of Committee: National Diabetes and Digestive and Kidney
Diseases Advisory Council; Kidney, Urologic and Hematologic Diseases
Subcommittee.
Date: September 9, 2015.
Open: 1:00 p.m. to 3:00 p.m.
Agenda: To review the Division's scientific and planning
activities.
Place: National Institutes of Health, Building 31, 31 Center
Drive, Conference Room 7, Bethesda, MD 20892.
Closed: 3:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Building 31, 31 Center
Drive, Conference Room 7, Bethesda, MD 20892.
Contact Person: Brent B. Stanfield, Ph.D., Director, Division of
Extramural Activities, National Institutes of Diabetes And Digestive
and Kidney Diseases, 6707 Democracy Blvd. Room 715, MSC 5452,
Bethesda, MD 20892, (301) 594-8843, stanfibr@niddk.nih.gov.
Name of Committee: National Diabetes and Digestive and Kidney
Diseases Advisory Council; Digestive Diseases and Nutrition
Subcommittee.
Date: September 9, 2015.
Open: 1:00 p.m. to 3:00 p.m.
Agenda: To review the Division's scientific and planning
activities.
Place: National Institutes of Health, Building 31, 31 Center
Drive, Conference Room 6, Bethesda, MD 20892.
Closed: 3:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Building 31, 31 Center
Drive, Conference Room 6, Bethesda, MD 20892.
Contact Person: Brent B. Stanfield, Ph.D., Director, Division Of
Extramural Activities, National Institutes of Diabetes And Digestive
and Kidney Diseases, 6707 Democracy Blvd. Room 715, MSC 5452,
Bethesda, MD 20892 (301) 594-8843, stanfibr@niddk.nih.gov.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Information is also available on the Institute's/Center's home
page: www.niddk.nih.gov/fund/divisions/DEA/Council/coundesc.htm.,
where an agenda and any additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: July 29, 2015.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-19024 Filed 8-3-15; 8:45 am]
BILLING CODE 4140-01-P
